What was studied?
A 68-week randomized trial enrolled 338 adults with overweight or obesity without diabetes. The active semaglutide and liraglutide comparison was open-label, while matched placebo comparisons were blinded. Lifestyle counseling accompanied the interventions.
What did the researchers report?
Average body-weight reduction was greater in the semaglutide active group than in the liraglutide active group. The publication also compared weight-loss thresholds and adverse-event profiles.
What are the limits?
The open-label active comparison, differences in trial regimens and discontinuation rules belong in the interpretation. This does not establish a universal ranking across every population or formulation. Pharmaceutical trial results should not be assigned to laboratory catalog materials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.